Future studies should involve more indicators, especially biomarkers such as leptins, C-reactive protein, and TNF-α, and should have expanded sample size and better study design to better reflect the effect of wearable technology intervention on breast cancer survivors. The gene discussed is TNF; the disease is breast carcinoma.